SEARCH

SEARCH BY CITATION

References

  • 1
    Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007; 357: 1472-1475.
  • 2
    Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006; 354: 1813-1826.
  • 3
    Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant. 2008; 14: 316-322.
  • 4
    Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007; 109: 3658-3666.
  • 5
    Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006; 107: 3481-3485.
  • 6
    Hegenbart U, Niederwieser D, Sandmaier BM, et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol. 2006; 24: 444-453.
  • 7
    Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007; 357: 258-265.
  • 8
    Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008; 111: 2505-2515.
  • 9
    Hehlmann R, Berger U, Pfirrmann M, et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood. 2007; 109: 4686-4692.
  • 10
    Schlenk RF, Pasquini MC, Perez WS, et al. HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant. 2008; 14: 187-196.
  • 11
    Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008; 358: 1909-1918.
  • 12
    Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998; 352: 1087-1092.
  • 13
    Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006; 91: 513-521.
  • 14
    Gratwohl A. Bone marrow transplantation activity in Europe 1990. European Group for Bone Marrow Transplantation (EBMT). Bone Marrow Transplant. 1991; 8: 197-201.
  • 15
    Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008; 42( suppl 1): S70-S72.
  • 16
    Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008; 112: 1992-2001.
  • 17
    Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annu Rev Public Health. 1999; 20: 145-157.
  • 18
    Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modelling strategies for improved prognostic prediction. Stat Med. 1984; 3: 143-152.
  • 19
    von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007; 4: e296.
  • 20
    Allogeneic bone marrow transplantation for leukaemia in Europe. Report from the Working Party on Leukaemia, European Group for Bone Marrow Transplantation. Lancet. 1988; 1: 1379-1382.
  • 21
    Schetelig J, Bornhauser M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. J Clin Oncol. 2008; 26: 5183-5191.
  • 22
    Gratwohl A, Dohler B, Stern M, Opelz G. H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. Lancet. 2008; 372: 49-53.
  • 23
    Petersdorf EW. Risk assessment in haematopoietic stem cell transplantation: histocompatibility. Best Pract Res Clin Haematol. 2007; 20: 155-170.
  • 24
    Dickinson AM, Harrold JL, Cullup H. Haematopoietic stem cell transplantation: can our genes predict clinical outcome? Expert Rev Mol Med. 2007; 9: 1-19.
  • 25
    Bucher C, Stern M, Buser A, et al. Role of primacy of birth in HLA-identical sibling transplantation. Blood. 2007; 110: 468-469.
  • 26
    Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007; 25: 4246-4254.